Dr Reddy's March quarter results were higher-than-estimated with revenue growing 22.8% year-over-year, driven by robust growth of 67.6% in U.S. generics and 25.7% in Russia and CIS. The launch of generic fexofenadine pseudoephedrine during the quarter lifted U.S. growth. However, Indian formulations grew only 5.1% year-over-year.
Adjusted net profit rose 46.6% year-over-year as EBITDA margin improved 80 bps to 21.6%. during the quarter.Going ahead, the U.S., India and Russia generic formulations are expected to drive earnings. Analysts expect the stock to deliver 26% over the next one year.